{"prompt": "['OSTPDL1', 'Page 32 of 60', 'Treat as Grade 3 to 4', 'Grade 3 or 4', 'Discontinue avelumab', 'If improves to baseline:', 'Severe new symptoms;', 'therapy', 'Taper steroids over at', 'new / worsening hypoxia;', 'Hospitalize', 'least 6 weeks', 'life-threatening', 'Pulmonary and ID consults', 'If not improving after 48', '2 to 4 mg/kg/day', 'hours or worsening:', 'methylprednisolone IV or', 'Add additional', 'equivalent', 'immunosuppression', 'Add prophylactic', '(e.g., infliximab,', 'antibiotics for', 'cyclophosphamide,', 'opportunistic infections', 'intravenous', 'Consider bronchoscopy,', 'immunoglobulin, or', 'lung biopsy', 'mycophenolate mofetil)', 'Hepatic irAEs', 'Grade of Liver Test', 'Elevation (NCI-CTCAE', 'Management', 'Follow-up', 'v4)', 'Grade 1', 'Continue avelumab', 'Continue liver function', 'AST or ALT > IULN to 3.0', 'therapy', 'monitoring', 'X IULN and/or total', 'If worsens:', 'bilirubin >IULN to 1.5 X', 'Treat as Grade 2 or 3-4', 'IULN', 'Grade 2', 'Delay avelumab therapy', 'If returns to Baseline:', 'AST or ALT > 3.0 to < 5 X', 'Increase frequency of', 'Resume routine', 'IULN and/or total bilirubin', 'monitoring to every 3', 'monitoring, resume', '> 1.5 to < 3 X IULN', 'days', 'avelumab therapy', 'If elevations persist > 5 to', '7 days or worsen:', '0.5 to 1 mg/kg/day', 'methylprednisolone or', 'oral equivalent and when', 'LFT returns to Grade 1 or', 'baseline, taper steroids', 'over at least 1 month,', 'consider prophylactic', 'antibiotics for', 'opportunistic infections,', 'and resume avelumab', 'therapy', 'Grade 3', 'Discontinue avelumab', 'If returns to Grade 2:', 'AST or ALT >5-20 X IULN', 'therapy', 'Taper steroids over at', 'and/or total bilirubin > 3- -', 'Increase frequency of', 'least 1 month', '10 X IULN', 'monitoring to every 1-2', 'If does not improve in > 3', 'Grade 4', 'days', 'to 5 days, worsens or', 'AST or ALT >20 IULN', '1 to 2 mg/kg/day', 'rebounds:', 'Bilirubin > 10 IULN', 'methylprednisolone IV or', 'Add mycophenolate', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: 01-26-201 APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 33 of 60', 'IV equivalent 2.0', 'mofetil 1 gram (g) twice', 'mg/kg/day', 'daily', 'Add prophylactic', 'If no response within an', 'antibiotics for', 'additional 3 to 5 days,', 'opportunistic infections', 'consider other', 'Consult gastroenterologist', 'immunosuppressants per', 'Consider obtaining', 'local guidelines', 'MRI/CT scan of liver and', 'liver biopsy if clinically', 'warranted', 'Endocrine irAEs', 'Patients experiencing symptoms such as fatigue, myalgia, impotence, mental', 'status changes, constipation, or other symptoms thought to be associated with', 'endocrine abnormalities should be evaluated for thyroid, pituitary, or adrenal', 'endocrinopathies and an endocrinologist should be consulted.', 'Patients with Grade 2 hypothyroidism should be evaluated by an endocrinologist', 'for further management. Patients with Grade 2 hypothyroidism adequately', 'managed with thyroid hormone replacement may continue on protocol therapy.', 'Patients with Grade 3 or greater hypothyroidism will be considered to have had a', 'dose-limiting toxicity. These patients should be managed according to table', 'below and evaluation by an endocrinologist is recommended for further', 'management. Patients who enter the study on thyroid replacement should have', 'their medication adjusted to maintain TSH in the normal range.', 'Endocrine Disorder', 'Management', 'Follow-up', 'Asymptomatic TSH', 'Continue avelumab therapy', 'abnormality', 'If TSH < 0.5 X LLN, or TSH > 2x IULN, or consistently', 'out of range in 2 subsequent measurements: include', 'T4 at subsequent cycles as clinically indicated;', 'consider endocrinology consult', 'Symptomatic', 'Evaluate endocrine', 'If improves (with or', 'endocrinopathy', 'function', 'without hormone', 'Consider pituitary scan', 'replacement):', 'Symptomatic with', 'Taper steroids over at', 'abnormal ab/pituitary', 'least 1 month and', 'scan:', 'consider prophylactic', 'Delay avelumab therapy', 'antibiotics for', '1 to 2 mg/kg/day', 'opportunistic infections', 'methylprednisolone IV or', 'Resume avelumab therapy', 'oral equivalent', 'Participants with adrenal', 'Initiate appropriate', 'insufficiency may need to', 'hormone therapy', 'continue steroids with', 'No abnormal lab/pituitary', 'mineralocorticoid', 'MRI scan but symptoms', 'component', 'persist:', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: RPPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}